Chardan Capital Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $28.00

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price decreased by equities research analysts at Chardan Capital from $30.00 to $28.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other equities analysts have also issued reports on FDMT. Morgan Stanley reduced their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday. Finally, Bank of America dropped their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.38.

4D Molecular Therapeutics Stock Up 4.8 %

FDMT stock opened at $4.16 on Tuesday. The business has a 50 day moving average of $5.12 and a 200-day moving average of $8.37. The firm has a market cap of $192.31 million, a PE ratio of -1.46 and a beta of 2.81. 4D Molecular Therapeutics has a 12-month low of $3.92 and a 12-month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. PNC Financial Services Group Inc. raised its stake in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after buying an additional 9,737 shares during the period. Finally, Velan Capital Investment Management LP bought a new stake in 4D Molecular Therapeutics during the 4th quarter valued at $56,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.